Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Annexon Inc(ANNX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANNX
09/23/2026: ANNX (4-star) is currently NOT-A-BUY. Pass it for now.
Annexon Inc is a clinical-stage biotechnology company developing C1q-inhibitor therapies aimed at addressing neuroinflammatory and complement-mediated diseases. The company is characterized by its focused R&D platform and a pipeline targeting high-need conditions like geographic atrophy. Its primary growth opportunity lies in successfully advancing these candidates through clinical trials to regulatory approval. Key risks include the binary nature of clinical trials, ongoing cash burn, and intense competition from larger, well-capitalized pharmaceutical firms. Annexon is best suited for investors with a high risk tolerance who are looking for exposure to biotechnology clinical milestones and understand that the stock lacks current commercial revenue.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Investors must have a high risk tolerance for clinical-stage binary outcomes. |
| Momentum investor | Weak fit | Momentum is conditional on positive clinical data readouts, which are infrequent. |
| Value investor | Weak fit | The company lacks earnings or revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital into research. |
| Low-risk investor | Weak fit | High clinical and financial risk makes this unsuitable for conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience massive swings based on clinical trial results. |
| Valuation risk | High | Without commercial products, valuation is speculative and highly sensitive to sentiment. |
| Competition risk (Complement pathway inhibitors) | High | Larger companies with established drugs can crowd out clinical adoption. |
| Business quality | Medium | The science is promising, but the business is currently an unproven R&D vehicle. |
| Dividend income | Low / none | This is a growth-stage company with no payout capacity. |
| Execution risk | High | Success depends entirely on meeting trial endpoints and securing regulatory approval. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 126.1% | Avg. Invested days 42 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 792.44M USD | Price to earnings Ratio - | 1Y Target Price 15.29 |
Price to earnings Ratio - | 1Y Target Price 15.29 | ||
Volume (30-day avg) 2.9M shares | Beta 1.22 | 52 Weeks Range 2.54 - 7.18 | Updated Date 09/23/2026 |
52 Weeks Range 2.54 - 7.18 | Updated Date 09/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.12 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biopharmaceutical R&D | Clinical trial development of C1q-targeting therapies for neurological diseases. | Annexon does not currently sell products; it spends money to develop potential drugs. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 615.43M | Price to Sales(TTM) - |
Enterprise Value 615.43M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.47 | Shares Outstanding 189.58M | Shares Floating 163.79M |
Shares Outstanding 189.58M | Shares Floating 163.79M | ||
Percent Insiders 0.42 | Percent Institutions 103 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Annexon Inc
Exchange NASDAQ | Headquarters Brisbane, CA, United States | ||
IPO Launch date 2020-07-24 | CEO, President & Director Mr. Douglas E. Love Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 92 | Website https://www.annexonbio.com |
Full time employees 92 | Website https://www.annexonbio.com | ||
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.